Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Emcure Pharma divests mRNA business for Rs 139.5 crore to Immunoscript Life Science
Emcure Pharmaceuticals said that its subsidiary at Gennova Biopharmaceuticals has executed a business transfer agreement for transfer of its mRNA business as a going concern on a slump sale basis to Immunoscript Life Science.
Gennova Biopharmaceuticals to transfer its mRNA business to Immunoscript Life Science
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis for a cash consideration of Rs 139.5 crore to Immunoscript Life Science on 10 July2026.
Bain Capital exits Emcure Pharma after selling remaining stake, ends 12-year bet
Shares of Emcure Pharmaceuticals Ltd ended at ₹1,881.90, up by ₹43.75, or 2.38%, on the BSE.
Stocks to buy or sell: Osho Krishan of Angel One suggests buying HDFC Bank, Emcure Pharma shares on 25 June - Mint
Stocks to buy or sell: Osho Krishan of Angel One suggests buying HDFC Bank, Emcure Pharma shares on 25 JuneMint
Emcure Pharma climbs after foreign brokerage reiterates Buy call, lifts target
Emcure Pharmaceuticals jumped 5.10% to Rs 1,882.40 after a foreign brokerage reiterated its 'Buy' rating on the stock and raised its target price to Rs 2,100 from Rs 1,970.
Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, Vedanta
Indian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but uncertainty persists due to mixed heavyweight stock trends. Investors are advised to focus on stock-specific opportunities as analysts maintain a cautious outlook.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Block deals: Four stocks see large trades worth over ₹2,000 crore on Tuesday; Check how they reacted
Barring Bluestone Jewellery, whose shares are trading with losses of over 5%, shares of Ajanta Pharma, Emcure Pharma, and Capital Small Finance Bank are trading with gains between 1% to 4% after their respective block deals on Tuesday.
Eight Pharma stocks that should be on your radar on Monday
Pharmaceutical companies reported a slew of updates over the weekend. Earnings reactions from KIMS, Global Health, Gland Pharma, Aarti Drugs, to a USFDA observation list for Emcure Pharma, these are the drugmakers that should be on your radar today.
Emcure Pharma receives 7 US FDA observations for Sanand formulations facility in Gujarat
On Friday (May 15), shares of Emcure Pharmaceuticals Ltd ended at ₹1,702.30, up by ₹28.90, or 1.73%, on the BSE.
Stocks to Watch today: Hero MotoCorp, Paytm, L&T, Bajaj Auto, Policybazaar
Stocks to Watch today, Wednesday, May 6, 2026: Vedanta, Zen Tech, Grasim Industries, PNB, and Emcure Pharma are among the top stocks to watch today
Emcure eyes India growth, global deals amid strong demand
Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in India and internationally. New products are expected to drive significant growth. Emcure's partnership with Novo Nordisk for GLP-1 therapies and a pipeline of complex injectables will support future momentum.